Thu, March 21, 2019
Wed, March 20, 2019
Tue, March 19, 2019
Mon, March 18, 2019
Fri, March 15, 2019
Thu, March 14, 2019
Wed, March 13, 2019
Tue, March 12, 2019
Mon, March 11, 2019
Fri, March 8, 2019
Thu, March 7, 2019
Wed, March 6, 2019
Tue, March 5, 2019
Mon, March 4, 2019
Fri, March 1, 2019
Thu, February 28, 2019
Wed, February 27, 2019
Tue, February 26, 2019
Mon, February 25, 2019
Fri, February 22, 2019
Thu, February 21, 2019
Wed, February 20, 2019

Matthew Harrison Maintained (SRPT) at Buy with Increased Target to $169 on, Mar 4th, 2019


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-169-on-mar-4th-2019.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $161 to $169 on, Mar 4th, 2019.

Matthew has made no other calls on SRPT in the last 4 months.



There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Matthew


  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $201 on, Friday, March 1st, 2019
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $231 on, Thursday, February 28th, 2019
  • Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $230 on, Thursday, February 28th, 2019

Publication Contributing Sources